Bagel, J., Armstrong, A.W., Warren, R.B., Papp, K.A., Thaçi, D., Menter, A., Cather, J., Augustin, M., Hippeli, L., Daamen, C. and Griffiths, C.E. 2023. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s117. DOI:https://doi.org/10.25251/skin.7.supp.117.